September 11, 2019
US Merck filed its PD-1 inhibitor Keytruda (pembrolizumab) for an additional indication of unresectable, advanced/relapsed esophageal cancer in Japan on September 10, the company’s local arm said the same day. The submission is supported by data from a global PIII...read more